NYSEAMERICAN:ARMP Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis $3.64 +0.19 (+5.51%) Closing price 10/23/2026 04:10 PM EasternExtended Trading$3.63 -0.01 (-0.27%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsNews and TrendsOwnershipSEC FilingsShort Interest About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Armata Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.44▼$3.8050-Day Range$2.78▼$5.8452-Week Range$2.74▼$14.98Volume115,589 shsAverage Volume105,516 shsMarket Capitalization$135.34 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingModerate Buy Company Overview Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for drug-resistant bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics. The company’s pipeline has included inhaled and intravenously administered phage candidates designed to treat serious infections caused by pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus. Its programs have been directed toward conditions including chronic pulmonary infections in people with cystic fibrosis, as well as bloodstream and other difficult-to-treat bacterial infections. Armata also develops engineered phages and phage-based combination therapies intended to improve antibacterial activity and address resistance. Armata is headquartered in Marina del Rey, California, and conducts research and clinical-development activities in the United States. The company was formerly known as AmpliPhi Biosciences and adopted the Armata Pharmaceuticals name in 2019. Its operations are led by President and Chief Executive Officer Todd R. Patrick.AI Generated. May Contain Errors. Read More Armata Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreARMP MarketRank™: 1.681475498115 of 5 starsArmata Pharmaceuticals scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingArmata Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialArmata Pharmaceuticals has a consensus price target of $15.00, representing about 312.1% upside from its current price of $3.64.Amount of Analyst CoverageArmata Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Armata Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Armata Pharmaceuticals are expected to decrease in the coming year, from $0.50 to ($2.04) per share.Read more about Armata Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.73% of the float of Armata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArmata Pharmaceuticals has a short interest ratio ("days to cover") of 5.99.Change versus previous monthShort interest in Armata Pharmaceuticals has recently increased by 0.08%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArmata Pharmaceuticals does not currently pay a dividend.Dividend GrowthArmata Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentArmata Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Armata Pharmaceuticals this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders84.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions3.57% of the stock of Armata Pharmaceuticals is held by institutions.Read more about Armata Pharmaceuticals' insider trading history. Receive ARMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARMP Stock News HeadlinesArmata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United StatesOctober 7, 2026 | prnewswire.comJonesTrading Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP)September 28, 2026 | theglobeandmail.comWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.October 25 at 1:00 AM | Digest Publishing (Ad)Armata Pharmaceuticals Receives Additional Non-Dilutive Funding To Support AP-SA02 Phase 3 DevelopmentSeptember 23, 2026 | marketscreener.comMArmata Gets $3.7M DoW Funding For AP-SA02 Phase 3 Development; Stock DownSeptember 23, 2026 | rttnews.comArmata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 DevelopmentSeptember 23, 2026 | prnewswire.comArmata Pharmaceuticals, Inc. Presents Data On Defined Genetic Diversity In AP-SA02 At ISSSI 2026September 22, 2026 | marketscreener.comMArmata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical IsolatesSeptember 21, 2026 | prnewswire.comSee More Headlines ARMP Stock Analysis - Frequently Asked Questions How have ARMP shares performed this year? Armata Pharmaceuticals' stock was trading at $6.28 at the beginning of the year. Since then, ARMP shares have decreased by 42.0% and is now trading at $3.64. How were Armata Pharmaceuticals' earnings last quarter? Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) released its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.18. The firm earned $2.51 million during the quarter, compared to analyst estimates of $0.40 million. Armata Pharmaceuticals had a negative trailing twelve-month return on equity of 12.24% and a negative net margin of 3,467.04%. Who are Armata Pharmaceuticals' major shareholders? Armata Pharmaceuticals' top institutional investors include Nisa Investment Advisors LLC (0.04%). View institutional ownership trends. How do I buy shares of Armata Pharmaceuticals? Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Armata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include Advanced Micro Devices (AMD), AnaptysBio (ANAB), Arcutis Biotherapeutics (ARQT), Cypherpunk Technologies (CYPH), iBio (IBIO), Precigen (PGEN) and Applied Therapeutics (APLT). Company Calendar Last Earnings8/12/2026Today10/25/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ARMP's financial health is in the Red zone, according to TradeSmith. ARMP has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:ARMP CIK921114 Webwww.armatapharma.com Phone(310) 655-2928Fax310-665-2963Employees61Year FoundedN/APrice Target and Rating Average Price Target for Armata Pharmaceuticals$15.00 High Price Target$15.00 Low Price Target$15.00 Potential Upside/Downside+312.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$173.80 million Net Margins-3,467.04% Pretax Margin-3,467.04% Return on Equity-12.24% Return on Assets32.16% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.11 Sales & Book Value Annual Sales$4.90 million Price / Sales27.62 Cash FlowN/A Price / Cash FlowN/A Book Value($6.00) per share Price / Book-0.61Miscellaneous Outstanding Shares37,180,000Free Float5,763,000Market Cap$135.34 million OptionableNot Optionable Beta1.40 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NYSEAMERICAN:ARMP) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Armata Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
